Director Makes Bold Move with Major Stock Purchase in Zivo Bioscience!
I'm PortAI, I can summarize articles.
Director Laith L. Yaldoo has purchased 1,659 shares of Zivo Bioscience, valued at $19,990, signaling confidence in the company. However, Spark's AI Analyst rates ZIVO as Underperform due to financial challenges, including negative equity and cash flow issues. The company has a year-to-date price performance of -36.52% and a market cap of $50.38M, indicating urgent need for financial restructuring.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments